Shenzhen Salubris Pharmaceuticals Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shenzhen Xinlitai Pharmaceutical Co., Ltd. (hereinafter referred to as "Xinlitai") was established in 1998 and listed on the Shenzhen Stock Exchange in 2009 (stock code: 002294). It is an innovation driven pharmaceutical enterprise based in China, facing the world, and integrating research, production, and sales. Xinlitai adheres to the sacred mission of "providing excellent medical products for human health", with high-quality innovative products and evidence-based medicine promotion as its core competitiveness, and strives to become a leading enterprise in the field of chronic diseases, mainly focusing on cardiovascular and cerebrovascular diseases. Xinlitai has successively undertaken more than 60 national major special projects and major scientific and technological projects at the national, provincial, and municipal levels during the 11th, 12th, and 13th Five Year Plans. It has won the "China Patent Gold Award" three times, and has been awarded honors such as "National Technology Innovation Demonstration Enterprise" and "Best Industrial Enterprise in China's Pharmaceutical R&D Product Line". |
| Headquarter | Shenzhen |
| Establish Date | 11/3/1998 |
| Listed Code | 002294.SZ |
| Listed Date | 9/10/2009 |
| Chairman | Kevin Sing Ye. |
| CEO | Yan Jie. |
| Website | www.salubris.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
